(Reuters) – Swiss drugmaker Roche said first-quarter sales dropped 7% on falling demand for its COVID-19 therapies and diagnostics kits.
Quarterly group revenue fell to 15.3 billion Swiss francs ($17.2 billion), the company reported on Wednesday, beating market expectations of 14.8 billion francs.
The company does not report earnings for its first and third quarter.
(Reporting by Ludwig Burger, editing by Kirsti Knolle)
